Clinical Trial Update: Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment [NA]

View source ↗

Summary

A study evaluating a combination of a neoantigen-based peptide vaccine, a PD-1 inhibitor, and radiotherapy for advanced non-small cell lung cancer that progress…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Neoantigen-based Peptide Vaccine
• PD-1 inhibitor

Snippet

Sponsor: The First Affiliated Hospital of Nanchang University | Conditions: Advanced NSCLC | NA | Status: RECRUITING